On June 6, Docusign reported results for its fiscal 2026 first quarter (which ended April 30), and management increased its full-year revenue guidance, which signals clear momentum across the business ...

The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.

DocuSign has experienced a notable decline in its stock price, dropping by 15.61% over the past week. This movement comes amidst a series of analyst reports maintaining a ‘Hold ...

Piper Sandler analysts emphasized the large reduction in billings growth for fiscal year 2026 and highlighted ongoing macroeconomic uncertainties as reasons for maintaining a cautious outlook on ...

According to InvestingPro analysis, the stock appears undervalued at current levels, with strong financial metrics including a 79.25% gross profit margin and impressive 30.58% return on assets.

Docusign (NASDAQ: DOCU) stock plunged 19.3% through 11:11 a.m. ET this morning despite "beating earnings" on both top and bottom lines last night. Heading into the company's fiscal Q1 2026 ...

The company also announced an additional $1 billion stock buyback, taking its share repurchase plan to $1.4 billion. DocuSign shares are down more than 16% year to date.